ACG Clinical Guideline: Primary Sclerosing Cholangitis

doi:10.1038/ajg.2015.112

Practice Guideline

. 2015 May;110(5):646-59; quiz 660.

doi: 10.1038/ajg.2015.112. Epub 2015 Apr 14.

ACG Clinical Guideline: Primary Sclerosing Cholangitis

Keith D Lindor¹, Kris V Kowdley², M Edwyn Harrison³; American College of Gastroenterology

Affiliations

¹ 1] College of Health Solutions, Arizona State University, Phoenix, Arizona, USA [2] Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, Arizona, USA.
² Liver Care Network and Organ Care Research, Swedish Medical Center, Seattle, Washington, USA.
³ Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, Arizona, USA.

PMID: 25869391
DOI: 10.1038/ajg.2015.112

Practice Guideline

ACG Clinical Guideline: Primary Sclerosing Cholangitis

Keith D Lindor et al. Am J Gastroenterol. 2015 May.

. 2015 May;110(5):646-59; quiz 660.

doi: 10.1038/ajg.2015.112. Epub 2015 Apr 14.

Authors

Keith D Lindor¹, Kris V Kowdley², M Edwyn Harrison³; American College of Gastroenterology

Affiliations

¹ 1] College of Health Solutions, Arizona State University, Phoenix, Arizona, USA [2] Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, Arizona, USA.
² Liver Care Network and Organ Care Research, Swedish Medical Center, Seattle, Washington, USA.
³ Division of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, Arizona, USA.

PMID: 25869391
DOI: 10.1038/ajg.2015.112

Abstract

Primary sclerosing cholangitis is a chronic cholestatic liver disease that can shorten life and may require liver transplantation. The cause is unknown, although it is commonly associated with colitis. There is no approved or proven therapy, although ursodeoxycholic acid is used by many on an empiric basis. Complications including portal hypertension, fat-soluble vitamin deficiency, metabolic bone diseases, and development of cancers of the bile duct or colon can occur.

PubMed Disclaimer

Cited by

Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis.
Takinami M, Ono A, Kawabata T, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Kenmotsu H, Naito T, Murakami H, Endo M, Kiyohara Y, Yasui H, Niwakawa M, Takahashi T. Takinami M, et al. Invest New Drugs. 2021 Dec;39(6):1716-1723. doi: 10.1007/s10637-021-01136-z. Epub 2021 May 28. Invest New Drugs. 2021. PMID: 34046801 Free PMC article.
Clinical characteristics and outcomes of primary sclerosing cholangitis and ulcerative colitis in Japanese patients.
Kumagai J, Taida T, Ogasawara S, Nakagawa T, Iino Y, Shingyoji A, Ishikawa K, Akizue N, Yamato M, Takahashi K, Ohta Y, Hamanaka S, Okimoto K, Nakamura M, Ohyama H, Saito K, Kusakabe Y, Maruoka D, Yasui S, Matsumura T, Sugiyama H, Sakai Y, Mikata R, Arai M, Katsuno T, Tsuyuguchi T, Kato N. Kumagai J, et al. PLoS One. 2018 Dec 20;13(12):e0209352. doi: 10.1371/journal.pone.0209352. eCollection 2018. PLoS One. 2018. PMID: 30571774 Free PMC article.
Intrahepatic cystic biliary dilatation constitutes a significant prognostic factor in patients with primary sclerosing cholangitis.
Nguyen L, Cazzagon N, Corpechot C, El Mouhadi S, Lemoinne S, Chazouillères O, Arrivé L. Nguyen L, et al. Eur Radiol. 2019 Mar;29(3):1460-1468. doi: 10.1007/s00330-018-5697-3. Epub 2018 Aug 29. Eur Radiol. 2019. PMID: 30159619
Liver manifestations and complications in inflammatory bowel disease: A review.
Gaspar R, Branco CC, Macedo G. Gaspar R, et al. World J Hepatol. 2021 Dec 27;13(12):1956-1967. doi: 10.4254/wjh.v13.i12.1956. World J Hepatol. 2021. PMID: 35070000 Free PMC article. Review.
A composite score using quantitative magnetic resonance cholangiopancreatography predicts clinical outcomes in primary sclerosing cholangitis.
Vuppalanchi R, Are V, Telford A, Young L, Mouchti S, Ferreira C, Kettler C, Gromski M, Akisik F, Chalasani N. Vuppalanchi R, et al. JHEP Rep. 2023 Jun 29;5(10):100834. doi: 10.1016/j.jhepr.2023.100834. eCollection 2023 Oct. JHEP Rep. 2023. PMID: 37663118 Free PMC article.

See all "Cited by" articles

References

1. J Gastroenterol Hepatol. 2012 Jul;27(7):1150-8 - PubMed
1. World J Hepatol. 2014 Apr 27;6(4):178-87 - PubMed
1. Clin Gastroenterol Hepatol. 2014 Oct;12(10):1733-8 - PubMed
1. Nat Genet. 2011 Jan;43(1):17-9 - PubMed
1. Lancet. 2013 Nov 9;382(9904):1587-99 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wolters Kluwer
Other Literature Sources
- The Lens - Patent Citations Database

[1] J Gastroenterol Hepatol. 2012 Jul;27(7):1150-8 - PubMed

[2] J Gastroenterol Hepatol. 2012 Jul;27(7):1150-8 - PubMed

[3] World J Hepatol. 2014 Apr 27;6(4):178-87 - PubMed

[4] World J Hepatol. 2014 Apr 27;6(4):178-87 - PubMed

[5] Clin Gastroenterol Hepatol. 2014 Oct;12(10):1733-8 - PubMed

[6] Clin Gastroenterol Hepatol. 2014 Oct;12(10):1733-8 - PubMed

[7] Nat Genet. 2011 Jan;43(1):17-9 - PubMed

[8] Nat Genet. 2011 Jan;43(1):17-9 - PubMed

[9] Lancet. 2013 Nov 9;382(9904):1587-99 - PubMed

[10] Lancet. 2013 Nov 9;382(9904):1587-99 - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

ACG Clinical Guideline: Primary Sclerosing Cholangitis

Affiliations

ACG Clinical Guideline: Primary Sclerosing Cholangitis

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources